Factors associated with non use of adjuvant trastuzumab in older patients with HER2+breast cancer.

被引：0
|
作者：
Luis, Ines Vaz
Lin, Nancy U.
Keating, Nancy Lynn
Barry, William Thomas
Lii, Joyce
Burstein, Harold J.
Winer, Eric P.
Freedman, Rachel A.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
601
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2+ Breast Cancer: A Survey of Oncologists
    Hurria, Arti
    Wong, F. Lennie
    Pal, Sumanta
    Chung, Cathie T.
    Bhatia, Smita
    Mortimer, Joanne
    Somlo, George
    Hurvitz, Sara
    Villaluna, Doojduen
    Naeim, Arash
    [J]. ONCOLOGIST, 2009, 14 (09): : 883 - 890
  • [32] Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+breast cancer patients and financial impact of its use
    Lazaro Cebas, Andrea
    Cortijo Cascajares, Susana
    Pablos Bravo, Siria
    Goyache Goni, Maria Del Puy
    Gonzalez Monterrubio, Gema
    Perez Cardenas, Maria Dolores
    Ferrari Piquero, Jose Miguel
    [J]. JOURNAL OF BUON, 2017, 22 (02): : 334 - 339
  • [33] AXL is a potential druggable target in trastuzumab resistance in HER2+breast cancer patients.
    Adam-Artigues, Anna
    Cervera, Raimundo
    Javier Arenas, Enrique
    Braso-Maristany, Fara
    Martinez-Sabadell, Alex
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Simon, Soraya
    Poveda, Jesus
    Burgues, Octavio
    Rovira, Ana
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Eroles, Pilar
    Prat, Aleix
    Arribas, Joaquin
    Miguel Cejalvo, Juan
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [34] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14): : 1273 - 1283
  • [35] Adjuvant trastuzumab for HER2-positive breast cancer
    Spicer, J
    Harries, M
    Ellis, P
    [J]. LANCET, 2005, 366 (9486): : 634 - 634
  • [36] Phase I trial of gemcitabine plus trastuzumab and pertuzumab in previously treated metastatic HER2+breast cancer.
    Soliman, Hatem Hussein
    Khambati, Fatema
    Han, Hyo S.
    Ismail-Khan, Roohi
    Loftus, Loretta S.
    Minton, Susan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [38] Breast MRI as a radiomic biomarker of immune enrichment in HER2+breast cancer.
    Kennedy, Laura
    Durenberger, Grace
    Stanton, Sasha E.
    Vinayak, Shaveta
    Dintzis, Suzanne
    Partridge, Savannah C.
    Gadi, Vijayakrishna K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+breast cancer
    Miller, K. D.
    Steding, C. E.
    Prasad, N.
    Rojas, L. A.
    Herbert, B-S
    [J]. CANCER RESEARCH, 2012, 72
  • [40] Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2+Breast Cancer
    Song, Patrick N.
    Mansur, Ameer
    Lu, Yun
    Della Manna, Deborah
    Burns, Andrew
    Samuel, Sharon
    Heinzman, Katherine
    Lapi, Suzanne E.
    Yang, Eddy S.
    Sorace, Anna G.
    [J]. CANCERS, 2022, 14 (04)
12345